{"product_id":"ligand-pestle-analysis","title":"Ligand Pharmaceuticals PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eNavigate regulatory shifts, patent dynamics, and technological change with our PESTLE Analysis of Ligand Pharmaceuticals—concise, expert-driven insights that reveal external risks and opportunities shaping the company’s future; buy the full report to get the complete breakdown, ready-to-use in presentations and strategic plans.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing legislation and IRA impacts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act's Medicare drug price negotiation could cut prices for top drugs by up to 25%–50% in selected classes, reducing royalty revenues for Ligand partners that generate Medicare sales; Ligand reported $166.7m in 2024 revenue largely from royalties, so negotiated pricing materially risks top-line receipts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal regulatory harmonization efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIncreased FDA‑EMA cooperation on common technical standards has cut parallel review redundancies, helping Ligand partners accelerate global launches; EMA‑FDA pilot programs reported a 10–15% faster review cadence in 2023–24, shortening time‑to‑market for Captisol‑enabled drugs and potentially bringing forward royalty streams.\u003c\/p\u003e\n\u003cp\u003eFaster approvals can boost Ligand’s royalty visibility—Captisol‑containing approvals rose 18% from 2022–2024—yet political shifts in the US, EU or UK risk abrupt regulator reprioritization or personnel turnover, which could temporarily reverse these gains and delay revenue recognition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical trade and IP protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrade tensions between the US and emerging markets risk weakening IP enforcement for Ligand’s licensed technologies; in 2024, global pharma revenue at stake from IP leakage was estimated at $40–60 billion annually, affecting royalty streams tied to deals like those contributing to Ligand’s $394.6 million 2024 revenue.\u003c\/p\u003e\n\u003cp\u003ePolitical stability and adherence to international patent treaties are crucial as Ligand expands; over 70% of pharma R\u0026amp;D revenue depends on strong IP regimes in key markets such as China and India.\u003c\/p\u003e\n\u003cp\u003eRegional conflicts can disrupt supply chains and chemical component manufacturing—UN trade disruption indices showed a 12% increase in pharma supply-chain incidents in 2023—requiring Ligand to include scenario planning and diversified sourcing in strategic risk models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment funding for biomedical research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic funding from NIH and other agencies—NIH budget ~$47.5B in FY2024—underpins early-stage biotech that licenses Ligand’s discovery tools, sustaining deal flow for partnerships.\u003c\/p\u003e\n\u003cp\u003eCuts from fiscal conservatism or reprioritization could shrink the preclinical pipeline, reducing prospective licensees and royalty upside for Ligand.\u003c\/p\u003e\n\u003cp\u003eTargeted rare-disease subsidies and programs (e.g., 2024 orphan drug incentives) boost demand for specialized solubility platforms like Captisol, supporting revenue diversification.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNIH budget ~47.5B (FY2024)\u003c\/li\u003e\n\u003cli\u003eReduced public spending risks fewer license deals\u003c\/li\u003e\n\u003cli\u003eOrphan\/rare-disease subsidies increase Captisol demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare policy shifts and insurance coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChanges in US healthcare policy on mandates and reimbursement directly affect revenue for Ligand’s partnered drugs; Medicare Part B\/ D reimbursement shifts in 2024–2025 and inflation-linked payment updates altered net prices by an estimated 2–4% annually, impacting royalty flows.\u003c\/p\u003e\n\u003cp\u003eIf policy or legislation raises patient cost-sharing, prescription volumes may drop—analysts should track bills on drug pricing and universal coverage proposals that could expand or compress Ligand’s addressable market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement changes drive royalties\u003c\/li\u003e\n\u003cli\u003eHigher out-of-pocket costs risk lower volumes\u003c\/li\u003e\n\u003cli\u003eUniversal coverage proposals could expand TAM\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare cuts threaten Ligand royalties; faster approvals and NIH funding partly offset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare negotiation (IRA) risks 25–50% price cuts on top drugs, threatening Ligand’s royalty-driven $166.7m 2024 revenue; FDA‑EMA faster reviews (10–15% faster) and 18% rise in Captisol approvals (2022–24) improve royalty timing, while IP risks in China\/India and 12% rise in supply‑chain incidents (2023) pose downside; NIH funding ~$47.5B (FY2024) supports partner pipeline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLigand 2024 revenue (royalties)\u003c\/td\u003e\n\u003ctd\u003e$166.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCaptisol approvals growth (2022–24)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA‑EMA faster reviews\u003c\/td\u003e\n\u003ctd\u003e10–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH budget FY2024\u003c\/td\u003e\n\u003ctd\u003e$47.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply‑chain incidents rise (2023)\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Ligand Pharmaceuticals across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current industry data and trends to identify threats and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise PESTLE snapshot of Ligand Pharmaceuticals that highlights regulatory and intellectual property risks, market and technological opportunities in drug discovery partnerships, and macroeconomic and healthcare policy sensitivities—ideal for quick sharing in presentations or team briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rate environment and biotech capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe cost of capital remains a primary driver for biotech; US prime rates rose to ~8.5% in 2023–24, keeping WACC high and constraining small-cap R\u0026amp;D and licensing demand for Ligand’s technologies.\u003c\/p\u003e\n\u003cp\u003eHigher rates through 2024 curtailed venture investment and dealflow, reducing new partnership cadence and pressure-testing Ligand’s service revenues.\u003c\/p\u003e\n\u003cp\u003eAs markets expect rate cuts into late 2025, Bloomberg consensus projects Fed funds near 4.5% by end-2025, potentially boosting biotech IPOs and VC activity and supporting renewed demand for Ligand’s platform and royalties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on manufacturing costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhile Ligand’s royalty-heavy model cushions revenue, Captisol production exposes the company to raw material and energy costs; US CPI was 3.4% in 2024 and global oil averaged ~$84\/barrel in 2024, raising input cost risk. Persistent inflation could compress margins if existing long-term supply contracts prevent passing increased costs to partners. Q4 2025 PPI for specialty chemicals rose ~6.2% YoY, a key indicator to monitor for operational profitability pressure. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty revenue diversification and stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLigand's economic health hinges on royalties from a diversified portfolio of marketed drugs, which in 2025 generated recurring revenue—royalty and license revenue was $382.9 million in FY2024—helping offset single-product risk.\u003c\/p\u003e\n\u003cp\u003eThis passive income stream is attractive in volatile markets where traditional R\u0026amp;D faces high binary risk, supporting predictable cash flow and valuation resilience.\u003c\/p\u003e\n\u003cp\u003eThe company’s strategy to acquire royalty interests—deploying capital selectively during downturns—enabled purchases at attractive valuations, contributing to a 12% CAGR in royalty revenue from 2021–2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs a global technology licensor receiving royalties in euros and yen, Ligand faces USD exchange-rate risk; a 10% USD appreciation vs EUR in 2024 would cut translated euro-denominated royalties by roughly 10%, impacting non-operational results.\u003c\/p\u003e\n\u003cp\u003eAnalysts must model translation exposure—Ligand reported $1.2bn revenue in 2024; even a 5% USD move could change reported quarterly earnings by millions and alter international competitiveness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExposure to EUR and JPY royalties\u003c\/li\u003e\n\u003cli\u003e10% USD move materially affects translated income\u003c\/li\u003e\n\u003cli\u003e5% shifts can change quarterly EPS by millions\u003c\/li\u003e\n\u003cli\u003eForecasts must include translation and hedging assumptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation trends in the pharma industry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eConsolidation in pharma peaked with 2023–2024 deal value ~225 billion USD globally; M\u0026amp;A often prompts pipeline rationalization, risking termination of programs using Ligand technologies during buy-side reviews.\u003c\/p\u003e\n\u003cp\u003eLarge acquirers offer wider commercial reach—top 10 firms account for ~40% of global Rx sales—yet integration uncertainty can delay milestones and royalty streams for Ligand partners.\u003c\/p\u003e\n\u003cp\u003eLigand mitigates risk by diversifying partnerships and maintaining a broad portfolio of \u0026gt;400 partnered programs, reducing exposure to any single partner's restructuring.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eM\u0026amp;A deal value ~225B USD (2023–24)\u003c\/li\u003e\n\u003cli\u003eTop 10 firms ≈40% global Rx sales\u003c\/li\u003e\n\u003cli\u003eLigand partners \u0026gt;400 programs\u003c\/li\u003e\n\u003cli\u003eRisk: pipeline cuts, delayed milestones, royalty volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLigand's $382.9M royalties and 12% CAGR weather high rates, FX and input-cost risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh US rates (~8.5% in 2023–24) raised WACC, slowing VC\/deals; Fed expected ~4.5% end-2025 may revive IPOs\/partnering. Ligand’s $382.9M FY2024 royalty\/license cushion reduces binary R\u0026amp;D risk, but Captisol faces input-cost pressure (2024 US CPI 3.4%, oil ~$84\/bbl). FX exposure (EUR\/JPY) means USD moves materially affect reported revenue; royalty CAGR ~12% (2021–24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 royalty revenue\u003c\/td\u003e\n\u003ctd\u003e$382.9M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty CAGR (2021–24)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CPI 2024\u003c\/td\u003e\n\u003ctd\u003e3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg oil 2024\u003c\/td\u003e\n\u003ctd\u003e$84\/bbl\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS rates 2023–24\u003c\/td\u003e\n\u003ctd\u003e~8.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eLigand Pharmaceuticals PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Ligand Pharmaceuticals PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use; it covers Political, Economic, Social, Technological, Legal, and Environmental factors specific to Ligand’s business and industry, with no placeholders or teasers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752102343033,"sku":"ligand-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ligand-pestle-analysis.png?v=1772237615","url":"https:\/\/matrixbcg.com\/products\/ligand-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}